This startup cultivates specific strains of psilocybin mushrooms for research and therapeutic applications. By focusing on breeding and optimization, they aim to provide consistent, high-quality fungi for use in mental health treatments and scientific studies.
Funding
Funding not disclosed
Founders
Product
Problem
The therapeutic use of psilocybin mushrooms is limited by the inconsistent potency and chemical profiles of wild or conventionally cultivated fungi. This variability makes it difficult to conduct rigorous scientific research and develop standardized dosing for mental health treatments.
Solution
Psymbiotika Lab addresses this challenge by breeding and genotyping specific strains of psilocybin mushrooms to enhance their properties and functionality. They leverage genomic insights to cultivate "designer shrooms" with consistent and predictable levels of psilocybin and other active compounds. These genotyped and phenotyped mushrooms can be upscaled for targeted research and therapeutic markets, providing a reliable source of fungal material for clinical applications. By innovating allelic diversity behind the genes that produce psilocybin, Psymbiotika Lab aims to advance both physical and mental health outcomes.
Target Audience
The primary customers are clinical researchers, pharmaceutical companies, and mental health practitioners seeking a consistent and reliable source of psilocybin mushrooms for research, drug development, and therapeutic applications.
Features
- Proprietary breeding program focused on enhancing specific traits in psilocybin mushrooms
- Genomic analysis and genotyping to ensure consistent chemical profiles
- Cultivation of "designer shrooms" with tailored levels of psilocybin and other compounds
- Upscaling capabilities for supplying research institutions and therapeutic markets
- Focus on allelic diversity to create novel mushroom varieties